Company intelligence / Profile preview

Fosun Kairos

Shanghai, Shanghai Municipality, Chinaen.fosun.com ↗

Ownership: Private
Employees: ~63
Development stage: Commercial

Overview

Yi Kai Da, the company’s flagship autologous anti-CD19 CAR-T therapy, was the first and remains the only CAR-T product approved for second-line use in mainland China. It has been included in over a hundred commercial health insurance plans. The company operates more than 170 treatment centers across China. Other pipeline assets are at preclinical or early clinical stages targeting hematologic malignancies and solid tumors.

Therapeutic areas: Oncology
Modalities: Autologous CAR-T cell therapiesBispecific antibodiesBiological products
Industry: Biotech

Drug pipeline

4 assets

FKC118

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Former joint venture with Kite Pharma Inc.ongoing license agreement with Kite Pharma regarding key technology/IP

Beyond the preview

Go deeper on Fosun Kairos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fosun Kairos.

Explore the full profile